FDA
-
-
-
-
-
-
-
Merrimack Receives $225 Million Milestone Payment from Ipsen
-
-
-
-
-
-
-
Merrimack Reports Full Year 2022 Financial Results
-
-
-
-
-
-
-
Merrimack (MACK) Reports Ipsen Phase III RESILIENT Trial Did Not Meet Endpoints
-
-
-
-
-
-
-
Merrimack Reports Third Quarter 2020 Financial Results
-
-
-
-
-
-
-
Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review
-
-
-
-
-
-
-
Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer
-
-
-
-
-
-
-
Hercules Capital Announces Additional Portfolio Company Liquidity Events and Congratulates Its Portfolio Companies on Their Achievements
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

